Abbott and Celera, Armed with CE Mark for Viral-Load HIV Test, Take on Roche in Europe | GenomeWeb

Sidling up to Roche Molecular, Abbott and Celera Diagnostics have received the CE Mark certification for their real-time PCR HIV viral load assay, and will begin competing against the market leader in Europe this week.

The new test runs on Abbott's m2000 real-time PCR instrument, which has also received a CE Mark, but has not yet been submitted for clearance with the FDA, said Don Braakman, an Abbott spokesperson, adding that the company will be submitting the test for US approval in 2005.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.